2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Vertex Pharmaceuticals company profile · cystic fibrosis & precision medicines · history · financial snapshot · S&P 500 rank #87 · 福泰製藥公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | VRTX (NASDAQ) |
| Company | Vertex Pharmaceuticals Incorporated |
| GICS sector / industry | Health Care (XLV) / Biotechnology |
| S&P 500 rank (by weight) | #87 · 0.19% (Oct 29, 2026) |
| Sector rank (by market cap) | #13 in Health Care (Oct 29, 2026) |
| Share price (frozen benchmark) | $540.00 (Oct 29, 2026) |
| Headquarters | Boston, Massachusetts |
| Founded | 1989 |
| CEO | Reshma Kewalramani (since April 2020) |
| Employees | ≈6,400 (2025) |
| Market cap | $136.87B (Oct 29, 2026) |
| SEC filings | SEC EDGAR — Vertex Pharmaceuticals Incorporated filings (company search) |
WHAT IT DOES
Vertex Pharmaceuticals is a biotechnology company that discovers, develops and sells precision medicines for serious diseases, built on a dominant cystic fibrosis franchise. FY2025 total revenues were $12.00B, up 9%, of which product revenues were $11.97B.
The cystic fibrosis franchise is the engine: TRIKAFTA/KAFTRIO alone produced $10.31B in FY2025, and the successor ALYFTREK, launched in late 2024, added $0.84B as patients transition to the once-daily regimen. Beyond cystic fibrosis, the company is commercializing CASGEVY, the first CRISPR-based gene-editing therapy, and JOURNAVX, a non-opioid medicine for acute pain.
Vertex reports as a single operating segment, so the revenue story is a product story: one disease area funds a pipeline spanning kidney disease, pain, diabetes and blood disorders, with research spending to match. GAAP operating income recovered to $4.17B in FY2025 after a loss-making FY2024 that carried heavy acquired-research charges.
PRODUCT REVENUES — FY2025
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| TRIKAFTA/KAFTRIO | $10.31B | 85.9% | +0.7% |
| ALYFTREK | $0.84B | 7.0% | — |
| Other product revenues | $0.82B | 6.8% | +5% |
| Other revenues | $0.03B | 0.3% | — |
| Total revenues | $12.00B | 100% | +9% |
HISTORY
| Year | Milestone |
|---|---|
| 1989 | Founded in Cambridge, Massachusetts, by Joshua Boger and colleagues to pursue structure-based drug design |
| 1995 | Lists its shares publicly |
| 1999 | Agenerase, its first marketed medicine, is approved for HIV |
| 2011 | Incivek (telaprevir) is approved for hepatitis C, a commercial breakthrough later withdrawn as treatment advanced |
| 2012 | Kalydeco (ivacaftor) is approved, the first medicine to treat the underlying cause of cystic fibrosis |
| 2015 | Orkambi is approved, extending cystic fibrosis treatment to the most common mutation combination |
| 2018 | Symdeko is approved, adding a further cystic fibrosis combination regimen |
| 2019 | Trikafta is approved, a triple combination that transforms cystic fibrosis care for most patients |
| 2020 | Reshma Kewalramani becomes chief executive officer in April 2020 |
| 2023 | Casgevy is approved, the first CRISPR-based gene-editing therapy, developed with CRISPR Therapeutics |
| 2024 | Alyftrek is approved in December 2024 as the once-daily successor to Trikafta |
| 2025 | Journavx is approved in January 2025 as a non-opioid treatment for acute pain; total revenues reach $12.00B |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Total revenues | $12.00B (+9% YoY) |
| Product revenues, net | $11.97B |
| Cost of sales | $1.65B |
| Operating income (GAAP) | $4.17B |
| Net income | $3.95B |
| Diluted EPS | $15.32 (vs a loss in FY2024) |
| Total assets | $25.64B (Dec 31, 2025) |
| Cash and short-term investments | $6.61B (Dec 31, 2025) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Vertex is the S&P 500’s cystic-fibrosis pure play: at a 0.19% index weight and the #13 market cap in Health Care, it is the index’s main exposure to rare-disease pricing power and precision-medicine economics.
Its product revenues are a standing read on rare-disease adoption — Trikafta-to-Alyftrek conversion, Casgevy uptake and Journavx launch progress show up here before they show up in sector aggregates.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Oct 29, 2026 close) |
| Financials | Vertex FY2025 Form 10-K (SEC EDGAR) and fourth-quarter/full-year 2025 results release (February 2026) |
| Sector classification | GICS (Biotechnology) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | VRTX(NASDAQ) |
| 公司 | Vertex Pharmaceuticals Incorporated |
| GICS 板塊/行業 | 醫療保健(XLV)/生物科技 |
| 標普500排名(按權重) | #87 · 0.19%(2026 年 10 月 29 日) |
| 板塊內排名(按市值) | 醫療保健第 #13(2026 年 10 月 29 日) |
| 股價(凍結基準) | $540.00(2026 年 10 月 29 日) |
| 總部 | 美國麻省波士頓 |
| 成立 | 1989 年 |
| 行政總裁 | Reshma Kewalramani(自 2020 年 4 月) |
| 員工 | ≈6,400(2025 年) |
| 市值 | $136.87B(2026 年 10 月 29 日) |
| SEC 申報 | SEC EDGAR — Vertex Pharmaceuticals Incorporated 申報(公司檢索) |
業務概覽
福泰製藥是一家生物科技公司,研發並銷售針對嚴重疾病的精準藥物,基礎是佔主導地位的囊性纖維化業務。FY2025 總收入為 $12.00B,同比增長 9%,其中產品收入為 $11.97B。
囊性纖維化業務是引擎:TRIKAFTA/KAFTRIO 在 FY2025 單獨貢獻 $10.31B,2024 年底上市的後續藥物 ALYFTREK 隨著患者轉用每日一次方案,新增 $0.84B。囊性纖維化以外,公司正在商業化首個 CRISPR 基因編輯療法 CASGEVY,以及非阿片類急性止痛藥 JOURNAVX。
福泰以單一經營板塊申報,因此收入故事即產品故事:一個疾病領域資助著涵蓋腎病、疼痛、糖尿病與血液疾病的管線,研發投入與之匹配。GAAP 營業利潤在 FY2025 恢復至 $4.17B,而 FY2024 因沉重的收購研發支出而虧損。
產品收入 — FY2025
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| TRIKAFTA/KAFTRIO | $10.31B | 85.9% | +0.7% |
| ALYFTREK | $0.84B | 7.0% | — |
| 其他產品收入 | $0.82B | 6.8% | +5% |
| 其他收入 | $0.03B | 0.3% | — |
| 總收入 | $12.00B | 100% | +9% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1989 | 由 Joshua Boger 等人在麻省劍橋創立,從事基於結構的藥物設計 |
| 1995 | 股份公開上市 |
| 1999 | 首個上市藥物 Agenerase 獲批,用於治療愛滋病 |
| 2011 | Incivek(telaprevir)獲批治療丙型肝炎,商業上取得突破,後因療法進步而撤市 |
| 2012 | Kalydeco(ivacaftor)獲批,首個針對囊性纖維化根本病因的藥物 |
| 2015 | Orkambi 獲批,將囊性纖維化治療擴展至最常見的突變組合 |
| 2018 | Symdeko 獲批,增加一種囊性纖維化聯合方案 |
| 2019 | Trikafta 獲批,三聯組合改變了大多數患者的囊性纖維化治療 |
| 2020 | Reshma Kewalramani 於 2020 年 4 月出任行政總裁 |
| 2023 | Casgevy 獲批,為首個 CRISPR 基因編輯療法,與 CRISPR Therapeutics 共同研發 |
| 2024 | Alyftrek 於 2024 年 12 月獲批,作為 Trikafta 的每日一次後續藥物 |
| 2025 | Journavx 於 2025 年 1 月獲批,為非阿片類急性止痛藥;總收入達 $12.00B |
競爭地位
財務快照 — FY2025
| 總收入 | $12.00B(同比 +9%) |
| 產品收入(淨額) | $11.97B |
| 銷售成本 | $1.65B |
| 營業利潤(GAAP) | $4.17B |
| 淨利潤 | $3.95B |
| 攤薄每股盈利 | $15.32(FY2024 為虧損) |
| 總資產 | $25.64B(2025 年 12 月 31 日) |
| 現金及短期投資 | $6.61B(2025 年 12 月 31 日) |
主要風險
對標普500的重要性
福泰是標普500中純粹的囊性纖維化標的:指數權重 0.19%、醫療保健板塊市值第 #13,是指數對罕見病定價能力與精準醫療經濟的主要敞口。
其產品收入是罕見病採用的常設讀數——Trikafta 向 Alyftrek 的轉換、Casgevy 的採用與 Journavx 的上市進展,往往先在此反映,再體現於板塊總數。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 29 日收盤) |
| 財務 | 福泰 FY2025 Form 10-K(SEC EDGAR)及 2025 年第四季度/全年業績發佈(2026 年 2 月) |
| 板塊分類 | GICS(生物科技),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-30 04:53 · updated 2026-11-15 00:14 · rev 7